Major players in the fertility drugs market are Merck & Co., Ferring Pharmaceuticals, Bayer, Berlex Laboratories Inc., Janssen Pharmaceutical Inc., Pfizer, Novartis AG, Procter & Gamble Pharmaceutical, Zydus Pharma and LIVZON.
The global drugs for infertility market is expected to grow from $3.48 billion in 2020 to $3.94 billion in 2021 at a compound annual growth rate (CAGR) of 13.2%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $4.83 billion in 2025 at a CAGR of 5%.
The fertility drugs market consists of sales of fertility drugs and related services used to aid the production of sperms and eggs in order to promote fertility among men and women. Fertility drugs are the primary treatment for infertility and increase the chances of producing an offspring by stimulating and regulating ovulation in women and increasing the sperm count in men.
The fertility drugs market covered in this market is segmented by gender into male; female. It is also segmented by route of administration into oral; intravenous; subcutaneous; intramuscular, by type of drug into prescription fertility drugs; over-the-counter fertility drugs and by distribution channel into hospital pharmacies; retail pharmacies; online pharmacies.
The side effects caused due to fertility drugs restricted the growth of the fertility drugs market.Fertility drugs can result in permanent as well as temporary side effects.
Temporary side effects includes bloating, headache, breast tenderness, upset stomach, hot flashes, and mood swings whereas the permanent side effects includes multiple pregnancies, ovarian hyperstimulation syndrome (OHSS).OHSS is a condition where the ovaries enlarge with fluids and may become life threating if left untreated.
For instance, the intake of Clomid (clomiphene citrate), a fertility drug for women, can result in OHSS along with abnormal vaginal/uterine bleeding, breast tenderness or discomfort, headache, nausea, vomiting, diarrhoea, flushing, blurred vision or other visual disturbances. The fear of potential side effects of the fertility drugs restrict the growth of the fertility drugs market.
In 2019, Ferring Pharmaceuticals, a USA based biopharmaceutical company, acquired USA commercialization rights of Ganirelix Acetate Injection from Sun Pharmaceutical Industries Ltd for an amount undisclosed.Through the acquisition, Ferring Pharmaceutical aims to broaden its medicine portfolio targeted towards reproduction.
Ganirelix Acetate Injection was approved by FDA in 2018 and is used to regulate premature luteinizing hormone (LH) levels in women undergoing fertility treatment. The Sun Pharmaceutical Industries Ltd is an India based manufacturer and seller of pharmaceutical formulations and active pharmaceutical ingredients.
The growth of the fertility drugs market is driven by the increasing rates of infertility across the globe.Infertility is the inability to conceive after trying for 12 consecutive months.
Fertility drugs are considered to be the primary treatment to treat infertility in men and women.The rising rates of infertility is attributed to physiological problems, hormone problems, and lifestyle or environmental factors.
To treat infertility problems in women, fertility drugs are used to regulate their ovulation cycles thus affecting the sale of fertility drugs. According to the USA National Survey of Family Growth (NSFG) in 2018, about 15.5% of all women who intend to become pregnant were infertile and 6.7% of married women aged 15 to 44 years were infertile. Further, in 2019, in India, 10% to 15% of couples in reproductive age group are suffering from infertility. Hence, the rising cases of infertility across the globe is increasing the demand for fertility drugs, resulting in the growth of fertility drugs market.
Our reports have been used by over 10K customers, including:
“Sialorrhoea – Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Sialorrhoea pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule...
“Axial spondyloarthritis - Pipeline Insight, 2021,” report provides comprehensive insights about 30+ companies and 30+ pipeline drugs in Axial spondyloarthritis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route...
Amyloidosis (Metabolic Disorder) - Drugs in Development, 2021 Summary This latest Pharmaceutical and Healthcare disease pipeline guide Amyloidosis - Drugs in Development, 2021, provides an overview of the Amyloidosis (Metabolic Disorders) pipeline landscape. Abnormal accumulation of amyloid...
N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021 Summary According to the recently published report ’N Sulphoglucosamine Sulphohydrolase - Drugs In Development, 2021’; N Sulphoglucosamine Sulphohydrolase (Sulfoglucosamine Sulfamidase or Sulphamidase or SGSH or EC 18.104.22.168) pipeline...
Tyrosine Protein Kinase Mer - Drugs In Development, 2021 Summary According to the recently published report ’Tyrosine Protein Kinase Mer - Drugs In Development, 2021’; Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 22.214.171.124) pipeline Target constitutes...
Aryl Hydrocarbon Receptor - Drugs In Development, 2021 Summary According to the recently published report ’Aryl Hydrocarbon Receptor - Drugs In Development, 2021’; Aryl Hydrocarbon Receptor (Class E Basic Helix Loop Helix Protein 76 or bHLHe76 or AHR) pipeline Target constitutes close to 29 molecules....
Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) - Drugs In Development, 2021 Summary According to the recently published report ’Neuropeptide Y Receptor Type 2 - Drugs In Development, 2021’; Neuropeptide Y Receptor Type 2 (NPY Y2 Receptor or NPY2R) pipeline Target constitutes close to 5...
162 pages •
By Global Industry Analysts
• Apr 2021
- Global Stem Cells Market to Reach $15.1 Billion by 2027
- Amid the COVID-19 crisis, the global market for Stem Cells estimated at US$9.1 Billion in the year 2020, is projected to reach a revised size of US$15.1 Billion by 2027, growing at aCAGR of 7.4% over the period 2020-2027. Adult Stem Cells, one of...
120 pages •
By Infiniti Research Limited
• May 2021
Global Microbiomes Market 2021-2025 The analyst has been monitoring the microbiomes market and it is poised to grow by $ 713.01 million during 2021-2025, progressing at a CAGR of over 24% during the forecast period. Our report on microbiomes market provides a holistic analysis, market size and forecast, trends, growth drivers,...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.